# Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer

> **NCT06356155** · PHASE2 · RECRUITING · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 32 (estimated)

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **DRUG:** Enfortumab vedotin
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06356155
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-22
- **Primary completion:** 2028-03
- **Final completion:** 2028-03
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2025-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06356155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06356155, "Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06356155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*